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DISSEMINATE study groupAbstract
Background: To evaluate the efficacy of Counselling and Advisory Care for Health (COACH) programme in
managing dyslipidaemia among primary care practices in Malaysia. This open-label, parallel, randomised controlled
trial compared the COACH programme delivered by primary care physicians alone (PCP arm) and primary care
physicians assisted by nurse educators (PCP-NE arm).
Methods: This was a multi-centre, open label, randomised trial of a disease management programme (COACH)
among dyslipidaemic patients in 21 Malaysia primary care practices. The participating centres enrolled 297
treatment naïve subjects who had the primary diagnosis of dyslipidaemia; 149 were randomised to the COACH
programme delivered by primary care physicians assisted by nurse educators (PCP-NE) and 148 to care provided by
primary care physicians (PCP) alone. The primary efficacy endpoint was the mean percentage change from baseline
LDL-C at week 24 between the 2 study arms. Secondary endpoints included mean percentage change from
baseline of lipid profile (TC, LDL-C, HDL-C, TG, TC: HDL ratio), Framingham Cardiovascular Health Risk Score and
absolute risk change from baseline in blood pressure parameters at week 24. The study also assessed the
sustainability of programme efficacy at week 36.
Results: Both study arms demonstrated improvement in LDL-C from baseline. The least squares (LS) mean change
from baseline LDL-C were −30.09% and −27.54% for PCP-NE and PCP respectively. The difference in mean change
between groups was 2.55% (p=0.288), with a greater change seen in the PCP-NE arm. Similar observations were
made between the study groups in relation to total cholesterol change at week 24. Significant difference in
percentage change from baseline of HDL-C were observed between the PCP-NE and PCP groups, 3.01%, 95% CI
0.12-5.90, p=0.041, at week 24. There was no significant difference in lipid outcomes between 2 study groups at
week 36 (12 weeks after the programme had ended).
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Conclusion: Patients who received coaching and advice from primary care physicians (with or without the
assistance by nurse educators) showed improvement in LDL-cholesterol. Disease management services delivered by
PCP-NE demonstrated a trend towards add-on improvements in cholesterol control compared to care delivered by
physicians alone; however, the improvements were not maintained when the services were withdrawn.
Trial registration: National Medical Research Registration (NMRR) Number: NMRR-08-287-1442
Trial Registration Number (ClinicalTrials.gov Identifier): NCT00708370
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Chronic diseases pose a significant disease burden causing
60% of all deaths worldwide [1]. Of these, 50% are attribu-
ted to cardiovascular diseases [1]. Low-and middle-income
countries are the biggest contributors to the increase in car-
diovascular disease burden [2]. Although it varies among
countries, the factors contributing to the escalating preva-
lence of chronic diseases are an ageing population, tobacco
use, unhealthy diet practices and physical inactivity, urban-
isation and global marketing [3], where half of these risk
factors are modifiable through behaviour modification.
Primary healthcare plays a pivotal role in gearing
patients towards positive behaviour management [4]. This
can be achieved through the use of a chronic disease man-
agement (CDM) model, which emphasises the integration
of several elements including multidisciplinary care deliv-
ery, patient education and provider decision support, self-
management and patient empowerment support, clinical
information technology, social support and quality incen-
tives within the primary health care system [5]. Although
studies have shown that chronic disease management are
associated with marked improvements in many clinical
outcomes associated with cardiovascular diseases [6-9];
many developing countries have yet to integrate CDM
into their primary healthcare systems due to limited
resources and systems orientated towards acute symptom-
atic care [4]. In addition, there is paucity of literature that
addresses the sustainability of chronic disease manage-
ment programmes in developing countries, in terms of its
efficacy and cost.
Malaysia is not immune to the rising tide of chronic dis-
eases, where cardiovascular diseases account for more
than 25% of all-cause mortality [10] and prevalence of car-
diovascular risk factors such as hypertension, diabetes
mellitus and dyslipidaemia has reached epidemic propor-
tions [11]. As a developing country, Malaysia is faced with
the expected challenges of implementing chronic disease
management in a resource-limited environment [12]. Al-
though there have been several disease management pro-
grammes implemented in Malaysia, evidence on their
cost-effectiveness, applicability and sustainability is lacking
[13]. Despite the often-repeated recommendations to in-
corporate multidisciplinary healthcare teams in chronicdisease care, access to allied health services is usually lim-
ited in a developing country like Malaysia. In addition, evi-
dence to support the use of nurse-assisted dyslipidaemia
management has been conflicting [14,15].
In view of the current lack of evidence on CDM effi-
cacy in a developing country such as Malaysia, we
designed a randomised controlled trial to assess the im-
pact of a chronic disease management programme,
COACH (Counselling and Advisory Care for Health) in
managing dyslipidaemia. The COACH programme used
in this study was intended to be modelled after the ori-
ginal COACH study [16,17]; however it was adjusted to
the local situation and limitations. The primary objective
of the DISSEMINATE study was to evaluate the efficacy
of the COACH programme led by primary care physi-
cians with assistance from nurse educators (PCP-NE)
compared to that led by the primary care physicians
alone (PCP) in improving serum low density level-
cholesterol (LDL-C) in dyslipidaemic subjects over a
period of 24 weeks. Secondary objectives included the
impact of the COACH programme in the two arms in
improving (i) patients’ lipid profiles i.e. High Density
Lipoprotein-Cholesterol (HDL-C), LDL-C, Total Choles-
terol (TC), Triglycerides (TG) and TC: HDL ratio, (ii)
blood pressure (systolic and diastolic), (iii) Framingham
cardiovascular risk, (iv) lifestyle modification (smoking
behaviour, diet, alcohol consumption, physical activity),
(v) programme satisfaction using a visual analogue scale
(VAS) and (vi) statin compliance. All outcomes were
assessed at 24 and 36 weeks of study duration. The out-
comes assessment at 36 weeks was designed to evaluate
the sustainability of programme effectiveness after the
programme ended at week 24.
Methods
Trial design
This was a multi-centre, open-label, parallel, randomised
trial of a disease management programme (COACH) led
by primary care physicians for dyslipidaemic patients.
Comparison was made between primary care physicians
who managed patients alone (PCP Group-Control arm)
versus those who were assisted by nurse educators
(PCP-NE Group-Intervention arm). Patients were
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laysian Medical Research Ethics Committee (MREC)
(National Medical Research Registration (NMRR) Num-
ber: NMRR-08-287-1442) and was conducted in compli-
ance with the Declaration of Helsinki and International
Conference on Harmonization (ICH) Good Clinical
Practice (GCP) guidelines, as well as local regulatory
requirements. No major changes were made to the trial
methodology after study initiation.
Site selection
Sites were selected based on their ability to recruit
patients and to commit to the project. In order to
achieve the recruitment rate and to provide a fair repre-
sentation of the patient population in Peninsula Malay-
sia, licensed primary healthcare centres around the
Klang Valley and other suburban towns were invited.
Other recruitment factors were availability of infrastruc-
ture such as internet line or fax machine, the investiga-
tor’s understanding of GCP, the availability of a site
coordinator and previous clinical trial experience. Thirty
five sites were approached and 21 sites actively partici-
pated in the study.
Subject recruitment
Patients who enrolled were newly diagnosed with dyslipi-
daemia. Subjects could be either male or female age 18
years or older. Besides having given informed consent,
subjects must have been contactable via telephone, live or
through short messaging services (SMS). Communication
with patients through these methods was a key element of
the COACH programme. Exclusion criteria applied
included participation in any other clinical research stud-
ies in the preceding 6 months, history of mental illness,
hypothyroidism, or presence of any other condition, which
the investigators judged could increase risk to the subject
and could interfere with the conduct of the study or inter-
pretation of the data.
Eligibility was defined by dyslipidaemia divided accord-
ing to 3 cardiovascular risk groups. Group I subjects were
dyslipidaemic with an LDL-C level within 160 to 250mg/
dL without concomitant cardiovascular risk factors. Group
II subjects had at least one additional cardiovascular risk
factor, excluding coronary heart disease (CHD) and dia-
betes mellitus (DM) with serum LDL-C level between 130
to 250mg/dL; Group III subjects consisted of those with
serum LDL-C level between 100 to 250mg/dL with pre-
existing CHD or CHD risk equivalent, such as DM or
other atherosclerotic diseases. The study subjects were
required to be lipid drug naïve and eligible for statin ther-
apy prior to study enrolment. Random numbers were gen-
erated by computer and printed in sealed envelopes. The
envelopes were subsequently allocated to each new patient
enrolled into the programme. A person independent ofthe study was tasked to assign a randomisation number to
a subject with known study identification number. The al-
location of the individual study group was then made
known when the envelopes were unveiled. Since COACH
was administered by the nurse educators independent of
the primary care doctor, knowledge of treatment alloca-
tion only became evident to the doctor when the subject
returned for his/her third scheduled visit (week 12). The
study duration was 36 weeks.Study procedure
All subjects received standard care and advice from their
primary care physicians as per the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel [ATP] III) guidelines
[18]. As part of the standard care, all subjects received a
COACH health booklet which was completed by the in-
vestigator during clinic visits. Subjects were expected to
attend clinic visits at week 12, 24 and 36 after baseline
randomisation. Statin dose was titrated according to car-
diovascular risk group as recommended by NCEP ATP
III Guidelines. Demographic data, primary diagnosis,
medical history, family history, smoking status, alcohol,
diet, physical activity, drug allergies and all other con-
comitant medications were captured in the study case
report form (CRF). Blood pressure reading, pulse rate,
general physical examination, 12-lead ECG, and blood
sampling were also conducted during study visits. All
blood samples were sent to a central laboratory for ana-
lysis. Telephone follow-up were made by site coordina-
tors at week 6 and 18 to ensure all patients completed
the health booklet correctly and complied with statin
treatment. Subject compliance to prescribed statin was
assessed by the primary care doctor and percentage
compliance was noted in the CRF.Study intervention
In addition to the standard care, subjects randomised to
the PCP-NE COACH Programme received bi-weekly
telephone follow-up by trained nurse educators for 24
weeks. The main purpose of the telephone call was to
provide patient’s self-management support and patient
empowerment and the discussion was guided by the
health education booklet. During the telephone follow-
up, the nurse educators provided reinforcement of the
health education information and reminded patients to
adhere to counselling advice and prescribed medications,
as well as to discuss any problems of adherence encoun-
tered with their physicians. Each telephone call lasted an
average of 15 min. Subjects also received phone calls
and SMS to remind them about forthcoming follow-up
visits. The study intervention was designed to support
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scribed care plan.
Study control
All subjects randomised to PCP COACH Programme
only received care from the site investigators as per nor-
mal practice. There was no additional telephone follow-
up and reinforcement by nurse educators. At the end of
24 weeks, the study period ended. However, all subjects
were required to attend follow-up visit at week 36, an
extension phase, during which both arms received stand-
ard care only. This was to evaluate whether there would
be sustained lipid control without reinforcement.
Outcome measures
The primary efficacy endpoint was the mean percent-
age change from baseline LDL-C at week 24 between
the two treatment arms. Other efficacy endpoints
included mean percentage change from baseline of
lipid profile (TC, LDL-C, HDL-C, TG, TC: HDL ratio),
Framingham Cardiovascular Heart Risk Score, and ab-
solute risk change from baseline in blood pressure
parameters (systolic and diastolic) at week 24 and week
36. Lifestyle change assessment of smoking behaviour,
food consumption, physical activity, alcohol consump-
tion, and medication compliance were also evaluated at
the end of the study.
Statistical analysis
The sample size was calculated to detect a clinically
meaningful difference of 10% in percentage change from
baseline in LDL-C levels with a standard deviation of
22.5%, a 2-sided, 5% significance level and 85% power.
During the implementation of the study, it was found
that there was potential treatment contamination of the
standard care arm where, behaviour modification oc-
curred due to subjects from both arms interacting with
each other. To overcome this, the sample size was
adjusted to account 20% of treatment contamination
(changing the effect size to 0.08%) and 10% attrition rate,
giving the study a total of 320 subjects.
The analysis was conducted using intention-to-treat
(ITT) analysis, which was defined as all lipid drug naïve
subjects who were newly diagnosed with dyslipidaemia,
eligible for statin therapy and were randomised with at
least 1 post-baseline response (efficacy or outcomes re-
search endpoints). Last observation carried forward was
used for missing data in the ITT analysis.
Statistical analysis was based on the mean percentage
change from baseline using a restricted maximum likeli-
hood (REML) model with repeated measures approach
(mixed model repeated measures [MMRM]). Signifi-
cance tests were based on the least squares (LS) mean
difference between treatment group to comparetreatment contrast for week 24 and week 36. The ana-
lyses conducted at 24 weeks evaluated the effectiveness
of the programme while analyses at 36 weeks assessed
the medium-term effectiveness of care by physicians
assisted by nurse educator (PCP-NE) compared with pri-
mary care physician care alone (PCP).
Results
In order to achieve a sample size of 320 subjects, 364
potential subjects were screened however, only 297
subjects met the eligible criteria and were randomised.
The period of patient recruitment was from September
2008 to July 2009. All patients were followed up for 36
weeks and the study was concluded in May 2010. One
hundred and forty nine subjects were randomised to
the PCP-NE COACH programme (Intervention) and
148 subjects to PCP COACH group (control). Of these,
122 (81.9%) from the intervention group and 123
(83.1%) from the standard care group completed the 36
weeks study. Figure 1 illustrates the trial profile for the
DISSEMINATE study.
There were no significant differences in subjects’ base-
line demographic characteristics and cardiovascular risk
factors (Table 1). All subjects had a primary diagnosis of
dyslipidaemia with a mean duration of 0.6 years from
disease onset in both groups. All subjects were pre-
scribed with HMG-CoA reductase inhibitors (statins).
The most common statins prescribed in each group
were lovastatin, simvastatin and atorvastatin. The me-
dian duration of statin treatment was 246 days. Approxi-
mately 99% and 95% of the patients in the intervention
and control arm respectively reported compliance to sta-
tin treatment.
At the end of the study, the ITT set consisted of data
from 132 and 131 subjects, from the intervention and
control arms respectively. At week 24, there was a trend
towards greater improvement in the intervention group.
The least squares (LS) mean changes from baseline
LDL-C were −30.09% and −27.54% for the intervention
group and control groups, respectively. The difference of
mean change in the intervention group was 2.55% lower
than the control group, however this was not significant
(p=0.288). At week 36, the LS mean of LDL-C between
the 2 study arms was comparable at −25.88 and −26.86,
for the intervention and control groups respectively. On
the other hand, there was a statistically significant differ-
ence when comparing the LS mean in the intervention
arm at week 24 and week 36 (p=0.016). This was due to
withdrawal of the COACH programme which resulted
in a diminution of the earlier LDL-C improvements seen
in the intervention arm.
Similar outcomes were observed with total cholesterol
(TC) level. The trend towards improved TC seen in the
intervention group compared with the control arm at 24
Subjects screened (n=364)
Subjects randomised (n=297) 
PCP-NE COACH (n=149) PCP COACH (n=148)
Completed the study at week 36
(n=123, 83.1%)
Completed the study at week 36
(n=122, 81.9%)
Discontinued (n=27)
Did not receive treatment : 0
Study drug related AE : 1
Loss to follow up : 9
Not willing to continue : 7




Did not receive treatment : 3
Study drug related AE
Loss to follow up : 2
Not willing to continue : 8








Figure 1 Study trial profile.
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ence was detected in triglyceride (TG) levels at week 24
and 36 between the 2 study arms. Table 2 and 3 illus-
trates the percentage change from baseline in LDL-C
and TC between the intervention and control group.
In contrast, a significant difference was detected in
high density lipoprotein-cholesterol (HDL-C) at week
24 between the intervention and control group with a
greater decrease in HDL. As illustrated in Table 2, the
difference in LS means of HDL-C between the inter-
vention and control group was 3.01 (95% CI 0.12 –
5.90), p=0.041 at week 24. However, this effect did not
persist beyond the duration of the intervention
(p=0.136) after week 24 (Table 3). These results at and
after week 24 were also reflected similarly in the total
cholesterol (TC): high-density lipoprotein cholesterol
(HDL-C) ratio.
There were no significant differences between both study
arms in relation to statin treatment compliance, systolic
and diastolic blood pressure and Framingham Coronary
Heart Disease risk scores at week 24. In terms of lifestyle
modification (i.e. cigarettes smoking, dietary changes, and
physical activity), no difference was observed between the
intervention and control group. In general, more than 80%
of the subjects were satisfied with the health booklet pro-
vided. Approximately 90% of subjects from the interven-
tion arm also expressed satisfaction with the programme in
helping them achieve health care goals through telephone
follow-up by nurse educators.Discussion
The COACH programme in this study utilised patient
education and empowerment as well as decision support
as interventional strategies to improve cholesterol control.
Both study arms had shown improved LDL-C and TC
level throughout the study period. The results were a
trend towards add-on improvements in both LDL-C and
TC levels when patients were co-managed by nurse educa-
tors, even though this was not statistically significant.
The lack of statistical significance was most likely
attributed to dilution of treatment effects with the use of
similar patient education methods in the control group
as well as in the intervention group, specifically, using
the COACH health booklet. The COACH programme
applied in our study delivered more comprehensive care
than usual compared to the typical Malaysian primary
care settings, which usually have little time or resource
to provide comprehensive disease management care as
part of daily practices [19]. As a result, in this study,
patients from both study arms would have benefited
from increased knowledge of their health conditions.
Although the COACH programme used in this study
was similar to other studies published by Vale et al. [16]
and Allen et al. [17], there are significant differences in
terms of study methodology. In the study conducted Vale
et al. [16], patients were continuously coached based on
previous assessment visit and progress monitored via
negotiated action plan. In addition, the Vale’s study fo-
cused on hospital based disease management programme.
Table 1 Baseline subjects demographics & characteristics
Intervention Arm (n=149) Control Arm (n=145)
Number of subjects; n (%)
Male 86 (57.7%) 83 (57.2%)
Female 63 (42.3%) 62 (42.8%)
Age, years; Mean (SD) 49.4 (11.1) 48.8 (9.9)
Race; Asian 149 (100.0) 145 (100.0)
Weight, kg; Mean(SD) 72.7 (15.2) 70.2 (15.1)
Height, cm; Mean (SD) 160.2 (8.2) 159.6 (9.3)
Body mass index, kg/m2; Mean (SD) 28.2 (4.9) 27.4 (4.9)
Mean duration of dyslipidaemia since onset (years) 0.6 0.6
Cardiovascular risk group a; n (%)
Group I 14 (9.4) 24 (16.6)
Group II 87 (58.4) 74 (51.0)
Group III 48 (32.2) 47 (32.4)
Age risk; n (%)
Male aged >45; Female aged >55 72 (48) 60 (41)
Male aged ≤45; Female aged ≤55 77 (52) 85 (59)
Family history b; n (%)
Yes 29 (19) 32 (22)
No 120 (81) 113 (78)
Blood pressure ≥ 140/90 mm Hg or antihypertensive medication at baseline; n (%)
Yes 89 (60) 88 (61)
No 60 (40) 57 (39)
Diabetes Mellitus; n (%)
Yes 47 (32) 47 (32)
No 102 (68) 98 (68)
CHD or CHD risk equivalent a; n (%)
Yes 1 (1) 1 (1)
No 148 (99) 144 (99)
Smoking Status
Never smoked 101 (68) 97 (67)
Ex-smoker 13 (9) 19 (13)
Current smoker 35 (23) 29 (20)
COACH = Counselling and Advisory Care for Health; SD = standard deviation; CHD = coronary heart disease; PCP = Primary Care Physicians; PCP-NE = Primary Care
Physicians assisted by Nurse Educators.
a Group I: subjects with dyslipidaemia with no other cardiovascular risk factors; Group II: subjects with dyslipidaemia with at least 1 additional cardiovascular risk
factor, excluding CHD and DM; Group III: subjects with dyslipidaemia with CHD or CHD risk equivalent.
b A history of premature coronary heart disease in a first-degree relative (parent or sibling). If the afflicted family member was male, premature coronary heart
disease would have occurred before age 55, and if female, before age 65.
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et al. [17] utilised the model of community-based partici-
patory research methodology to design the disease man-
agement programme, which consisted of enhanced usual
care with or without intensive disease management by
nurse practitioner/community health workers. Both stud-
ies had adopted many essential elements from the Chronic
Care Model [3], which had been proven to improve
chronic disease outcomes. In contrast to this study, theauthors had only adapted the previous COACH studies as
a patient support programme rather than a disease man-
agement programme due to severe resource limitation i.e.
lack of trained nursing support resulting in resistance
from local doctors to adopt a shared-care model on pa-
tient disease management counselling. As a result, the
nurse educators in this study had no access to patient’s
medical records and health education was reinforced using
the health education booklet only.
Table 2 Percent change from baseline in LDL-C, TC and HDL-C between intervention and control groups
Time point Outcomes LS Mean (SE) Difference in LS Means (%)
PCP-NE (n=132) PCP (n=131) PCP-NE versus PCP 95% Cl (%) p-value
Week 24 LDL-C −30.09 (2.03) −27.54 (2.03) −2.55 −7.26, 2.16 0.288
TC −22.97 (1.55) −20.80 (1.54) −2.17 −5.72, 1.38 0.229
HDL-C −2.60 (1.30) −5.61 (1.30) 3.01 0.12, 5.90 0.041
Week 36 LDL-C −25.88 (2.03) −26.86 (2.03) 0.98 −3.68, 5.65 0.679
TC −19.94 (1.53) −19.97 (1.52) 0.04 −3.43, 3.51 0.984
HDL-C −2.97 (1.42) −5.44 (1.41) 2.48 −0.79, 5.74 0.136
LS = Least Squares; SE = Standard Error; 95%; CI = 95% Confidence Interval; LDL-C = Low Density Lipoprotein Cholesterol; TC = Total Cholesterol; HDL-C = High
Density Lipoprotein Cholesterol; PCP = Primary Care Physicians; PCP-NE = Primary Care Physicians assisted by Nurse Educators.
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grammes involving additional support from nurses or
other disciplines is mixed. Our findings are comparable
with some studies [14,20] where reduction in blood
cholesterol was similarly equivocal due to the
Hawthorne effect among patients and healthcare provi-
ders, a change in people’s behaviour when being
observed. In addition, the study may have heightened
the awareness of disease management practices among
family physicians involved. However, studies published
by Vale et al. [16] and Allen et al. [17] that utilised a
similar programme, demonstrated significant improve-
ment in LDL-C and TC change from baseline when
patients with coronary heart diseases underwent the
programme. As opposed to our study, the positive out-
comes demonstrated in both the studies may be due to:
(1) the population enrolled i.e. the study recruited CHD
patients experiencing acute coronary syndrome who
were more motivated to change; (2) difference in setting
i.e. developed versus developing country; (3) difference
in prescription behaviour i.e. higher proportion of
patients prescribed with statin and with higher doses of
atorvastatin in the Vale et al. study (not commonly pre-
scribed among the doctors in the DISSEMINATE study).
Besides the 2 studies discussed above, there are alsoTable 3 Percent change from baseline in LDL-C, TC and
HDL-C between week 24 and 36
Study Arm Outcomes LS Mean (SE) p-value
Week 24 Week 36
PCP-NE (n=132) LDL-C −30.09 (2.03) −25.88 (2.03) 0.016
TC −22.97 (1.55) −19.94 (1.53) 0.018
HDL-C −2.60 (1.30) −2.97 (1.42) 0.768
PCP (n=131) LDL-C −27.54 (2.03) −26.86 (2.03) 0.695
TC −20.80 (1.54) −19.97 (1.52) 0.515
HDL-C −5.61 (1.30) −5.44 (1.41) 0.896
LS = Least Squares; SE = Standard Error; 95% CI = 95% Confidence Interval; LDL-C
= Low Density Lipoprotein Cholesterol; TC = Total Cholesterol; HDL-C = High
Density Lipoprotein Cholesterol; PCP = Primary Care Physicians; PCP-NE = Primary
Care Physicians assisted by Nurse Educators.other studies that have had positive results with multi-
disciplinary support [21-24].
The DISSEMINATE study had also revealed interest-
ing findings with regards to HDL-C decrease over the 6
months duration. This finding was inconsistent with
many clinical studies that reported mild improvement of
HDL-C with both drug treatment and disease manage-
ment care [25,26]. Several theories are hypothesised for
this outcome. First of all, there is some evidence that a
low fat diet reduces not just LDL-C but also HDL-C
[27-29]. Secondly, the COACH programme did not pro-
vide detailed nutritional education with information on
how to reduce high dietary fat intake while substituting
dietary fat with polyunsaturated fatty acids (PUFA) such
as olive oil. It is possible that both of these factors could
have resulted in the unexpected reduction in HDL-C
levels detected in our study.
Several limitations to our study are identified. In an ef-
fort to standardise patient care between different sites, a
health booklet was distributed to all subjects. As dis-
cussed above, this had diluted the difference in interven-
tional effects between control group and intervention
group. Also, the findings in the control arm would not
be generalise to the current primary care settings as it
had deviated from the normal local practice; however,
the outcomes from this study has demonstrated that
current chronic disease care in Malaysia primary care
practices are suboptimal and some improvements in
patient’s disease outcome can be achieved by simply
spending extra time to educate the patients on chronic
disease self-management and treatment compliance.
And furthermore, our study has also shown that the task
of personalised patient education does not have to be
purely the domain of the physicians but can also be pro-
vided by trained nurses. The study might have elicited a
more significant finding with addition of a third study
arm assessing the lipid outcomes among patients who
received “actual” standard care delivery by local physi-
cians. Though the primary outcome of the study was not
achieved, an additional post-hoc analysis may be able to
determine the proportion of uncontrolled dyslipidaemic
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the study follow-up. In the current analysis, the propor-
tion of patients who achieved target cholesterol level is
not known. A higher than expected attrition rate (initial
sample size calculation only accounted for 10% loss to
follow-up) could have also affected the final results of
the study.
Although our study showed that complementary nurse
support services in a disease management programme had
a positive trending impact on LDL-C and TC level com-
pared to physician management alone, the effect was not
sustainable after the intervention was withdrawn at week
24. Continuous therapeutic behavioural change seems to be
mandated to ensure long-term sustainable lipid control.
Conclusion
This study was designed as a trial in a “real-world” set-
ting and thus faced with its share of expected challenges.
The limitations of our study are acknowledged, and
some of the lack of effect may be attributable to similar-
ities between the management of patients in the inter-
vention and control group. Further study would be
warranted to build upon the results of this study while
addressing some of the limitations. Despite the lack of
statistical significance, the trend towards improved dysli-
pidaemia can be considered a success at some level. As
there is a paucity of published evidence on disease man-
agement programmes in this region, the data provided
by this study may be considered an indicator about the
potential role of disease management programmes in
developing Asian countries.
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